Full-Time

Director – Trial Master File Operations

Confirmed live in the last 24 hours

Eikon Therapeutics

Eikon Therapeutics

201-500 employees

Biotech startup developing innovative medicines

Compensation Overview

$200k - $218.5k/yr

+ Bonus + Equity Compensation

Senior, Expert

New York, NY, USA + 1 more

More locations: Hayward, CA, USA

The position requires a minimum of 3 days a week of onsite presence in either Jersey City, New York City, or Millbrae, CA.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Requirements
  • Minimum of 12+ years of experience with a Bachelor's degree, or 10+ years of experience with a post graduate degree
  • Strong understanding of regulatory requirements (e.g., ICH-GCP, FDA, EMA) and industry best practices for TMF operations
  • Experience with electronic Trial Master File systems (e.g., Veeva) and related technology platforms
  • Proficient knowledge of DIA TMF Reference Model
  • Demonstrated leadership skills to drive results to achieve optimal outcomes
  • Experience in managing a team and providing leadership to drive performance
  • Excellent communication skills and ability to collaborate with cross-functional teams
  • Ability to manage multiple projects simultaneously and meet tight deadlines
  • Ability to work onsite at least 3 days a week
Responsibilities
  • Lead the TMF Operations function to support Clinical Research and Development
  • Manage and oversee the TMF Operations team, including hiring, training, and performance management
  • Manage, provide direction, and maintain strong relationships with TMF third party vendors, including driving resolution of issues and remediation activities
  • Oversee on-site TMF facilities and off-site records storage facilities, including ensuring compliant chain-of-custody procedures
  • Develop and implement TMF processes and procedures, and TMF-related training materials that adhere to regulatory requirements and industry best practices
  • Develop and maintain strong relationships with internal stakeholders, including acting as a subject matter expert for TMF operations and requirements
  • Collaborate with cross-functional teams to ensure TMF completeness and accuracy throughout the trial lifecycle
  • Manage the quality control of TMF documents according to GCP and regulatory requirements from study start-up through inspection readiness and archival
  • Develop and establish TMF Key Performance Indicators (KPIs) globally for internal staff, CRO, and other stakeholders
  • Monitor and report TMF metrics to senior management, identifying areas for process improvement and implementing changes as needed
  • Monitor and report on TMF completeness and readiness to Clinical Trial Teams, including study specific TMF review activities
  • Serve as functional TMF inspection lead for regulatory inspections, providing relevant documents and information as required
  • Identify root cause of performance issues, determine the appropriate remediation, and implement solutions as required
  • Keep informed of regulatory changes and industry best practices related to TMF operations and coordinate with stakeholders to implement continuous operational excellence
  • Serve as eTMF platform business owner, including managing eTMF system configuration changes in accordance with established change control processes and monitoring the impact of configuration changes to optimize performance
  • Serve as sponsor archivist providing oversight of the contents and access to the archive
Desired Qualifications
  • Knowledge of clinical trial operations and processes, preferred

Eikon Therapeutics focuses on discovering and developing new medicines in the pharmaceutical industry. The company studies biological systems using advanced technologies to identify new drug targets, emphasizing the dynamic aspects of biology rather than just static chemical processes. Their team includes a diverse range of professionals, such as data scientists, chemists, and engineers, which allows them to combine science and engineering to create new therapies aimed at improving life. A key part of their approach is a proprietary single-molecule tracking (SMT) platform that visualizes protein movements in living cells, enabling them to analyze molecular interactions with high precision. Eikon Therapeutics aims to serve patients with serious diseases by developing effective treatments and generates revenue through the commercialization of these therapies.

Company Size

201-500

Company Stage

Series D

Total Funding

$1.1B

Headquarters

Hayward, California

Founded

2019

Simplify Jobs

Simplify's Take

What believers are saying

  • Eikon raised $350.7 million in Series D funding, supporting cancer drug development.
  • The SMT platform aligns with the growing demand for precision medicine and personalized therapies.
  • Eikon's AI-driven platform enhances drug discovery, leveraging the trend of AI in biotech.

What critics are saying

  • Increased competition from biotech unicorns like Abogen Biosciences with significant funding.
  • Potential challenges in scaling operations, evidenced by a large office lease in Jersey City.
  • Pressure to deliver on high expectations following substantial Series D funding.

What makes Eikon Therapeutics unique

  • Eikon's SMT platform offers real-time, molecular-resolution measurements of protein movement in living cells.
  • The company integrates AI and advanced automation for large-scale molecular interaction analysis.
  • Eikon's diverse team combines expertise in science, engineering, and technology for innovative therapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401(k) Company Match

Medical (premiums covered by Eikon at 95%)

Dental Insurance

Vision Insurance

Mental Health Support

Unlimited Paid Time Off

Paid Holidays

Life Insurance

Enhanced Parental Leave

Daily subsidized lunch program

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

5%
Chronicles Magazine
Mar 3rd, 2025
Family office investors demonstrate appetite for innovation and diversity

Another significant entity, Soros Capital - managed by Robert Soros, son of the billionaire George Soros - participated in a $350.7 million financing round for Eikon Therapeutics.

Business Wire
Feb 27th, 2025
Eikon Therapeutics Secures $350.7 Million Series D to Advance Clinical-Stage Programs and Future Pipeline

Eikon Therapeutics, Inc., a pivotal-stage biotechnology company that integrates advanced engineering with cutting-edge molecular and cell biology to a

Stat News
Feb 26th, 2025
Eikon Therapeutics raises $350 million

Eikon Therapeutics, led by former Merck RD head Roger Perlmutter, raised $350 million, bringing its total funding to $1.1 billion. The funds will support the clinical development of cancer drugs, including an immunotherapy in Phase 3 for melanoma and two PARP inhibitors. The financing round included investors like Lux Capital and Alexandria Venture Investments.

BioWorld
Feb 26th, 2025
Eikon raises $350.7M in Series D

Eikon Therapeutics Inc. has closed a $351 million series D funding round, marking the largest venture capital round of 2025 and the first series D of the year. This funding supports Eikon as it enters phase III in cancer treatment development.

Business Wire
Jan 7th, 2025
Eikon Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Eikon Therapeutics to present at the 43rd Annual J.P. Morgan Healthcare Conference.